scholarly journals The impact of prior malignancies on the development of second malignancies and survival in follicular lymphoma: A population‐based study

eJHaem ◽  
2020 ◽  
Vol 1 (2) ◽  
pp. 489-497
Author(s):  
Manette A.W. Dinnessen ◽  
Otto Visser ◽  
Sanne H. Tonino ◽  
Marjolein W.M. Poel ◽  
Nicole M.A. Blijlevens ◽  
...  
2012 ◽  
Vol 30 (15_suppl) ◽  
pp. 8049-8049 ◽  
Author(s):  
Abdulwahab J. Al-Tourah ◽  
Laurie Helen Sehn ◽  
Alden A Moccia ◽  
Randy D. Gascoyne ◽  
Joseph M. Connors

8049 Background: Several published series have established that the risk of transformation of follicular lymphoma (FL) to aggressive lymphoma is approximately 3% /year (15%-20% at 5 years). The addition of rituximab (R) to chemotherapy (immuno-chemotherapy) has significantly improved the outcome of patients with FL. The impact of immuno-chemotherapy on the risk of transformation remains unknown. We assessed whether the introduction of immuno-chemotherapy has altered this risk. Methods: We examined the Lymphoid Cancer Database of the British Columbia Cancer Agency for FL patients treated with immuno-chemotherapy. Inclusion criteria: FL grades 1-3A by WHO criteria; only patients requiring treatment at diagnosis were included. Exclusion criteria: FL grade 3B or composite histology (FL and DLBCL) at diagnosis; pts who received anthracycline-based chemotherapy; and HIV positivity. The diagnosis of transformation was confirmed by biopsy when possible (n=19; 79%) but patients who were considered to have transformed based on pre-defined clinical assessment (n=5; 21%) were also included in the analysis. Results: We identified 261 pts with FL grade 1-3A requiring treatment at diagnosis, who received immuno-chemotherapy; median f/u 47 months (0.2-116), median age, 61 y (34-86). Treatment: 243 (93%), R-CVP of which 145 (59%) also received maintenance R; 9 (4%), R-Fludarabine combination. 24 pts developed transformed aggressive lymphoma. The risk of transformation for the entire group was approximately 2% per year or 10% at 5 years. However, pts treated with maintenance R (n=151) had a lower risk of transformation compared to pts who only received R-chemo at induction (n= 110), 8% vs 20% at 5 years respectively, (P= 0.003). The post-transformation outcome remains poor with a median survival of 6 months. Conclusions: We and other groups have demonstrated that the risk of transformation from FL to aggressive lymphoma is approximately 15% to 20% by 5 years. Our study suggests that the introduction of immuno-chemotherapy has reduced this risk to less than 10%. This effect is particularly apparent when patients receive maintenance R. The outcome for patients who develop transformation remains poor.


2017 ◽  
Vol 1 (25) ◽  
pp. 2392-2398 ◽  
Author(s):  
Gudbjörg Jonsdottir ◽  
Sigrún H. Lund ◽  
Magnus Björkholm ◽  
Ingemar Turesson ◽  
Malin Hultcrantz ◽  
...  

Key Points Prior malignancy negatively impacts survival in patients with MM and >1 prior malignancy reduces survival even further. A prior malignancy diagnosis increases the risk of developing a second malignancy in patients with MM.


BMC Urology ◽  
2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Hui-Yin Yow ◽  
John Jeh Lung Tiong ◽  
Chun-Wai Mai ◽  
Esther van der Werf ◽  
Zulkifli Md Zainuddin ◽  
...  

Abstract Background Nocturia is widely prevalent condition with detrimental effects on quality of life and general health. In Malaysia, there is a lack of up-to-date prevalence study on nocturia. This study aimed to investigate the prevalence of nocturia and awareness pertaining to nocturia among Malaysian adults. Methods A cross-sectional population-based study was conducted among Malaysian adults aged ≥ 18 years old. The data was collected by mixed mode self-administered questionnaire from May 2019 to September 2019. Nocturia was defined as one or more voids at night. Results There were a total of 4616 respondents with 74.5% of response rate. The overall prevalence of nocturia among Malaysian adults was found to be 57.3%. In multivariate analysis, respondents aged 31–40 (1.91 [1.52–2.40]) or > 60 years old (2.03 [1.48–2.71]), and those who presented with hypertension (2.84 [2.28–3.53]), diabetes mellitus (1.78 [1.42–2.25]), renal disease (3.58 [1.93–6.63]) or overactive bladder (1.61 [1.10–2.35]) were associated with higher prevalence of nocturia. A significantly lower disease prevalence (p < 0.05) was noted among those aged 41–50 (0.73 [0.59–0.91]), male (0.78 [0.69–0.88]) and Chinese (0.47 [0.30–0.74]) or Indian (0.34 [0.21–0.54]) ethnicities. A total of 37.3% of respondents with nocturia reported that they faced sleeping difficulty about half the time or more after waking up in the middle of night. Those who had ≥ 2 voids per night experienced significantly higher mean bother score than those who had 1 void per night (p < 0.001). Approximately half (56.7%) of all respondents were not aware that night time urination is a medical condition. Only 25.2% of respondents with nocturia had sought medical attention for their nocturia. Conclusions The prevalence of nocturia among Malaysian adults is high and strongly influenced by age, sex, race and comorbidities. However, the general awareness pertaining to nocturia being a health issue remains low among Malaysians. The findings also highlighted the impact of nocturia on sleep and the need for nocturia education to better address this disease.


Sign in / Sign up

Export Citation Format

Share Document